Kavirajan, H. Neglect of Adverse Effects in Treatment Guidelines for Depression. American Journal of Psychiatry. 2024 Apr 1; 181(4): 342-5.

 

Kavirajan, H. Antidepressant Augmentation versus Switch in Treatment-Resistant Geriatric Depression.New England Journal of Medicine. 2023 May 25. ;388(21):2012-2013.doi: 10.1056/NEJMc2304804.

 

Kavirajan, H. Bupropion Switch for a Depressed Patient With Venlafaxine-Associated Night Sweats. J.Clin Psychopharmacol. Oct 2018.

 

Kavirajan HC, Lueck KL, Chuang K. Alternating Current Cranial Electrotherapy Stimulation (CES) in the treatment of depression. Cochrane Database of Systematic Reviews. July 2014.

 

Kavirajan H, Vahia IV, Thompson WK, Depp C, Allison M, Jeste DV. Attitude toward own aging and mental health in post-menopausal women. Asian Journal of Psychiatry. March 2014.

​

Kavirajan, H. Memantine: A comprehensive review of safety and efficacy. Expert Opinion on Drug Safety, January 2009.

 

Vahia IV, Chattillion E, Kavirajan H, Depp CA. Psychological protective factors across the lifespan: implications for psychiatry. Psychiatric Clin North Am. Mar 2011

 

Kavirajan H, Hays RD, Vassar S, Vickrey BG. Responsiveness and validity of the HUI (Health Utilities Index) in persons with dementia. Medical Care, June 2009

 

Kavirajan, H, Schneider L. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Lancet Neurology; Sept2007.

 

Kavirajan HC. Benefits of cognitive-motor intervention in MCI and mild to moderate Alzheimerdisease. (Letter) Neurology. 2005 Jul 26.

​

Asghar Ali AA, Espinoza R, Kavirajan H, Read S. The effect of risperidone on nursing burdenassociated with caring for patients with dementia. (Letter). J Am Geriatr Soc. Jul 2005.

 

Kavirajan H. Venlafaxine and SSRI Remission Data Revisited. (Letter) Br J Psychiatry. May 2004.

 

Kavirajan, H. The Amobarbital Interview Revisited: A Review of the Literature Since 1966. The Harvard Review of Psychiatry, Sept-Oct ’99.

​

Cochrane Clinical Answers

Kavirajan, H. In people with severe mental illnesses, what are the effects of crisis intervention? Cochrane Clinical Answers, 2017. DOI: 10.1002/cca.615. http://dx/doi.org/10.1002/cca.615

​

Kavirajan, H. Can brief school‐based interventions improve outcomes for substance‐using adolescents?Cochrane Clinical Answers, 2016. DOI: 10.1002/cca.1244: http://dx.doi.org/10.1002/cca.1244.

​

Kavirajan, H. Is intensive case management effective for people with severe mental illness?Cochrane Clinical Answers, 2017. DOI: 10.1002/cca.1632: http://dx.doi.org/10.1002/cca.1632.

 

Kavirajan, H. What are the effects of exercise for improving symptoms in adults with depression?Cochrane Clinical Answers, 2015. DOI: 10.1002/cca.355: http://dx.doi.org/10.1002/cca.355

 

Kavirajan, H. Is there randomized controlled trial evidence to support the use of adjunctive antioxidant treatments in people with schizophrenia? Cochrane Clinical Answers, 2016. DOI:10.1002/cca.1298: http://dx.doi.org/10.1002/cca.1298.

​

Kavirajan, H. How do tailored and non‐tailored internet‐based interventions for smoking cessation in adults compare with active and inactive controls and with each other? Cochrane Clinical Answers, 2018. DOI: 10.1002/cca.2055: http://dx.doi.org/10.1002/cca.2055.

​

Burch, J and Kavirajan, H. What are the benefits and harms of psychostimulant drugs for people with cocaine dependence? Cochrane Clinical Answers, 2018. DOI: 10.1002/cca.2105http://dx.doi.org/10.1002/cca.2105.

​

Kavirajan, H. How do single over‐the‐counter nicotine replacement therapy (NRT) agents compare with placebo/no NRT agents for smoking cessation? Cochrane Clinical Answers, 2018. DOI: 10.1002/cca.2197:

http://dx.doi.org/10.1002/cca.2197.

​

Kavirajan, H. How does implementation of a family‐based prevention program compare with no intervention or an adolescent‐based program provided only to prevent or reduce alcohol use in adolescents? Cochrane Clinical Answers, 2019. DOI: 10.1002/cca.2557: http://dx.doi.org/10.1002/cca.2557.

 

Kavirajan H. Can behavioral prevention interventions help women who have quit smoking while pregnant to maintain abstinence? Cochrane Clinical Answers, 2019. DOI: 10.1002/cca.2613http://dx.doi.org/10.1002/cca.2613.

 

Kavirajan, H. Do adjunctive interventions to standard behavioral support increase adherence to medications for tobacco dependence? Cochrane Clinical Answers, 2019. DOI: 10.1002/cca.2714http://dx.doi.org/10.1002/cca.2714.

 

Kavirajan, H. Can relapse prevention interventions help adults who have quit smoking while hospitalized to maintain abstinence? Cochrane Clinical Answers, 2019. DOI: 10.1002/cca.2614http://dx.doi.org/10.1002/cca.2614.

 

Kavirajan, H. Can relapse prevention interventions help adults who have quit smoking on their own to maintain abstinence? Cochrane Clinical Answers, 2019. DOI: 10.1002/cca.2615. http://dx.doi.org/10.1002/cca.2615.

 

Kavirajan, H. Can relapse prevention interventions help adults who have received assistance to stopsmoking maintain abstinence? Cochrane Clinical Answers, 2019. DOI: 10.1002/cca.2616http:dx.doi.org/10.1002/cca.2616.

 

Kavirajan, H. Can providing incentives to stop smoking to adult smokers of mixed populations increasequit rates? Cochrane Clinical Answers, 2019. DOI: 10.1002/cca.2670.http://dx.doi.org/10.1002/cca.2670.

 

Kavirajan, H. What are the effects of providing pregnant women with incentives to stop smoking?Cochrane Clinical Answers, 2019. DOI: 10.1002/cca.2669: http:dx.doi.org/10.1002/cca.2669.

 

Kavirajan, H. What are the benefits and harms of community pharmacy personnel interventions foradults wanting to quit smoking or reduce cigarette consumption? Cochrane Clinical Answers, 2020. DOI: 10.1002/cca.2827: http://dx.doi.org/10.1002/cca.2827.

 

Kavirajan, H. Can adding baclofen to psychosocial treatment improve outcomes for people with alcohol use disorder? Cochrane Clinical Answers, 2019. DOI: 10.1002/cca.2457: http:dx.doi.org/10.1002/cca.2457.

 

Kavirajan, H. In people with post‐traumatic stress disorder and comorbid substance use disorder, how dotrauma and non‐trauma‐focused psychological therapies affect outcomes? Cochrane ClinicalAnswers, 2016. DOI: 10.1002/cca.1428: http://dx.doi.org/10.1002/cca.1428.

 

Kavirajan, H. How does fluphenazine decanoate compare with other neuroleptics in people withschizophrenia? Cochrane Clinical Answers, 2016. DOI: 10.1002/cca.1200: http://dx.doi.org/10.1002/cca.1200.

 

Kavirajan, H. What are the benefits of interventions to reduce smoking in people receiving concurrent treatment for or in recovery from alcohol and other drug dependence? Cochrane Clinical Answers, 2017. DOI: 10.1002/cca.1683 http://dx.doi.org/10.1002/cca.1683.

 

Kavirajan, H. What are the effects of the Smoke-free Class Competition incentive for preventing smoking among children and adolescents? Cochrane Clinical Answers, 2017. DOI: 10.1002/cca.1832: http://dx.doi.org/10.1002/cca.1832

​

Kavirajan, H. In people with depression during opioid agonist treatment for opioid dependence, what are the effects of antidepressants? Cochrane Clinical Answers, 2016. DOI: 10.1002/cca.994http://dx.doi.org/10.1002/cca.994.Other 0-6/01